CD34 and acute myeloid leukemia: Expression of the interleukin-3 receptor alpha chain, CD123, in CD34+ CD38low/– AML blasts, is a prognostic factor for poor patient outcome (Vergez et al., 2011), and neutralizing antibody reduced AML burden and impaired secondary transplantation in NOD/SCID mice (Jin et al., 2009).